There are currently 29 active clinical trials seeking participants for Alzheimer's Disease research studies. The states with the highest number of trials for Alzheimer's Disease participants are Florida, California, New York and Arizona.
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
NCT03019757
Recruiting
The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/24/2023
Locations: The Ohio State University, Columbus, Ohio
Conditions: Alzheimer's Disease, Lewy Body Dementia, Parkinson's Disease
Register for Updates
Wake Forest Alzheimer's Disease Clinical Core
NCT03140865
Recruiting
Efforts to find treatments for AD have yielded only modest benefits, likely because longstanding AD pathological processes induce irreversible neurological compromise. These processes begin years before the onset of clinical symptoms. This possibility has been incorporated into a model describing stages of AD development, articulated by the NIA/Alzheimer's Association preclinical workgroup of which the Co-Director of the Kulynych Alzheimer's Research Center, Dr. Suzanne Craft, was a member. Acco... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
05/09/2024
Locations: Wake Forest Baptist Health, Winston-Salem, North Carolina
Conditions: Alzheimer's Disease, Mild Cognitive Impairment, Prediabetic State
Register for Updates
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
NCT05040217
Recruiting
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected by Alzheimer's disease and Mild Cognitive Impairment. The protein may also activate cells in the brain that have not yet deteriorated. Gene therapy refers to the use of a harmless virus to have brain cells make the potentially protective protein, BDNF.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
05/07/2024
Locations: University of California - San Diego, La Jolla, California +1 locations
Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Register for Updates
7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD
NCT05596994
Recruiting
The purpose of this research study is to investigate the effect of a light treatment on sleep, memory and brain function. In people with mild cognitive impairment (MCI) and Alzheimer's disease, sleep-wake disturbance is evident in up to 60% of patients. This can be caused by disruption of circadian rhythms and may affect our health and well-being. Circadian rhythms are the natural cycle of physical, mental, and behavior changes that the body goes through in a 24-hour cycle. Circadian rhythms are... Read More
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
05/02/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Register for Updates
Dominantly Inherited Alzheimer Network (DIAN)
NCT00869817
Recruiting
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida +23 locations
Conditions: Alzheimer's Disease
Register for Updates
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
NCT05658913
Recruiting
To collect Tau PET/CT imaging in older adults diagnosed with Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) in the Mismatch Prospective Cohort Study (MPC-Tau) study to determine relationship to clinical, cognitive, and other biomarker data. Findings from this study will likely provide insight into the phenotypic variability of Alzheimer's Disease and other related pathologies.
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/23/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Alzheimer's Disease
Register for Updates
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
NCT05738486
Recruiting
This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA.
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
04/23/2024
Locations: MD First Research - Chandler, Chandler, Arizona +43 locations
Conditions: Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
Register for Updates
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
NCT05744401
Recruiting
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
04/15/2024
Locations: Banner Alzheimer's Institute, Phoenix, Arizona +26 locations
Conditions: Alzheimer's Disease
Register for Updates
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
NCT05463731
Recruiting
The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's disease (AD).
Gender:
All
Ages:
Between 60 years and 85 years
Trial Updated:
04/15/2024
Locations: MD First Research - Chandler, Chandler, Arizona +68 locations
Conditions: Alzheimer's Disease
Register for Updates
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873
Recruiting
Background: About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective: To learn whether COX-1 and/or COX-2 is elevated in the brains of individuals with neurodegenerative brain disease compared to healthy volunteers. Eligibility: Adults age 18 years and older in good general he... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
04/13/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Dementia, Alzheimer's Disease, ALS, Parkinson's Disease
Register for Updates
Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2
NCT05837819
Recruiting
Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morning light exposure; and 3) all day light exposure.
Gender:
All
Ages:
65 years and above
Trial Updated:
04/09/2024
Locations: Icahn School of Medicine at Mount Sinai, Albany, New York +1 locations
Conditions: Alzheimer's Disease, Sleep Disturbance
Register for Updates
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
NCT05591027
Recruiting
This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.
Gender:
All
Ages:
Between 65 years and 85 years
Trial Updated:
04/05/2024
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: Mild Cognitive Impairment, Alzheimer's Disease
Register for Updates